nodes	percent_of_prediction	percent_of_DWPC	metapath
Oxaprozin—PTGS1—esophageal cancer	0.43	0.636	CbGaD
Oxaprozin—PTGS2—esophageal cancer	0.246	0.364	CbGaD
Oxaprozin—PTGS2—Cisplatin—esophageal cancer	0.0964	0.496	CbGbCtD
Oxaprozin—CYP2C9—Capecitabine—esophageal cancer	0.0651	0.335	CbGbCtD
Oxaprozin—CYP2C9—Cisplatin—esophageal cancer	0.0328	0.169	CbGbCtD
Oxaprozin—Gastrointestinal ulcer—Methotrexate—esophageal cancer	0.00272	0.0355	CcSEcCtD
Oxaprozin—Lung infection—Methotrexate—esophageal cancer	0.00256	0.0335	CcSEcCtD
Oxaprozin—Diuresis—Cisplatin—esophageal cancer	0.00247	0.0323	CcSEcCtD
Oxaprozin—Drug hypersensitivity—Capecitabine—esophageal cancer	0.0014	0.0183	CcSEcCtD
Oxaprozin—Infection—Carboplatin—esophageal cancer	0.000927	0.0121	CcSEcCtD
Oxaprozin—Haematemesis—Capecitabine—esophageal cancer	0.000814	0.0106	CcSEcCtD
Oxaprozin—Ulcer—Cisplatin—esophageal cancer	0.000811	0.0106	CcSEcCtD
Oxaprozin—Hearing impaired—Cisplatin—esophageal cancer	0.000806	0.0105	CcSEcCtD
Oxaprozin—Body temperature increased—Carboplatin—esophageal cancer	0.000737	0.00963	CcSEcCtD
Oxaprozin—Proteinuria—Capecitabine—esophageal cancer	0.000643	0.0084	CcSEcCtD
Oxaprozin—Protein urine present—Capecitabine—esophageal cancer	0.000635	0.00828	CcSEcCtD
Oxaprozin—Polyuria—Cisplatin—esophageal cancer	0.000634	0.00828	CcSEcCtD
Oxaprozin—Rectal haemorrhage—Capecitabine—esophageal cancer	0.000626	0.00817	CcSEcCtD
Oxaprozin—Deafness—Cisplatin—esophageal cancer	0.000622	0.00813	CcSEcCtD
Oxaprozin—Haemolytic anaemia—Cisplatin—esophageal cancer	0.000617	0.00805	CcSEcCtD
Oxaprozin—Cardiac failure congestive—Cisplatin—esophageal cancer	0.000614	0.00801	CcSEcCtD
Oxaprozin—Haematemesis—Methotrexate—esophageal cancer	0.000606	0.00791	CcSEcCtD
Oxaprozin—Renal failure acute—Cisplatin—esophageal cancer	0.000603	0.00787	CcSEcCtD
Oxaprozin—Ulcer—Capecitabine—esophageal cancer	0.000598	0.0078	CcSEcCtD
Oxaprozin—Hearing impaired—Capecitabine—esophageal cancer	0.000594	0.00775	CcSEcCtD
Oxaprozin—Fenbufen—PTGS1—esophageal cancer	0.000581	0.151	CrCbGaD
Oxaprozin—Anaphylactoid reaction—Cisplatin—esophageal cancer	0.000575	0.00751	CcSEcCtD
Oxaprozin—Gastrointestinal haemorrhage—Cisplatin—esophageal cancer	0.000557	0.00727	CcSEcCtD
Oxaprozin—Melaena—Capecitabine—esophageal cancer	0.000552	0.00721	CcSEcCtD
Oxaprozin—Oesophagitis—Capecitabine—esophageal cancer	0.000517	0.00674	CcSEcCtD
Oxaprozin—Urine output increased—Capecitabine—esophageal cancer	0.000511	0.00667	CcSEcCtD
Oxaprozin—Ecchymosis—Capecitabine—esophageal cancer	0.000511	0.00667	CcSEcCtD
Oxaprozin—Bifonazole—CYP19A1—esophageal cancer	0.000495	0.129	CrCbGaD
Oxaprozin—Sepsis—Capecitabine—esophageal cancer	0.000491	0.00641	CcSEcCtD
Oxaprozin—Proteinuria—Methotrexate—esophageal cancer	0.000479	0.00625	CcSEcCtD
Oxaprozin—Protein urine present—Methotrexate—esophageal cancer	0.000472	0.00617	CcSEcCtD
Oxaprozin—Pancreatitis—Cisplatin—esophageal cancer	0.000472	0.00616	CcSEcCtD
Oxaprozin—Sweating increased—Cisplatin—esophageal cancer	0.000469	0.00612	CcSEcCtD
Oxaprozin—Photosensitivity—Capecitabine—esophageal cancer	0.000467	0.0061	CcSEcCtD
Oxaprozin—Polyuria—Capecitabine—esophageal cancer	0.000467	0.0061	CcSEcCtD
Oxaprozin—Deafness—Capecitabine—esophageal cancer	0.000459	0.00599	CcSEcCtD
Oxaprozin—Vascular purpura—Capecitabine—esophageal cancer	0.000459	0.00599	CcSEcCtD
Oxaprozin—Pancytopenia—Cisplatin—esophageal cancer	0.000457	0.00597	CcSEcCtD
Oxaprozin—Oliguria—Methotrexate—esophageal cancer	0.000457	0.00596	CcSEcCtD
Oxaprozin—Glossitis—Methotrexate—esophageal cancer	0.000457	0.00596	CcSEcCtD
Oxaprozin—Hepatic failure—Capecitabine—esophageal cancer	0.000457	0.00596	CcSEcCtD
Oxaprozin—Haemolytic anaemia—Capecitabine—esophageal cancer	0.000455	0.00593	CcSEcCtD
Oxaprozin—Ulcer—Methotrexate—esophageal cancer	0.000445	0.00581	CcSEcCtD
Oxaprozin—Hepatic enzyme increased—Methotrexate—esophageal cancer	0.000445	0.00581	CcSEcCtD
Oxaprozin—Renal failure acute—Capecitabine—esophageal cancer	0.000445	0.0058	CcSEcCtD
Oxaprozin—Dermatitis exfoliative—Capecitabine—esophageal cancer	0.000435	0.00568	CcSEcCtD
Oxaprozin—Renal impairment—Capecitabine—esophageal cancer	0.000431	0.00563	CcSEcCtD
Oxaprozin—Vasculitis—Methotrexate—esophageal cancer	0.000431	0.00563	CcSEcCtD
Oxaprozin—Purpura—Capecitabine—esophageal cancer	0.000426	0.00556	CcSEcCtD
Oxaprozin—Acute coronary syndrome—Cisplatin—esophageal cancer	0.000423	0.00552	CcSEcCtD
Oxaprozin—Renal failure—Cisplatin—esophageal cancer	0.000422	0.00551	CcSEcCtD
Oxaprozin—Myocardial infarction—Cisplatin—esophageal cancer	0.000421	0.00549	CcSEcCtD
Oxaprozin—Lethargy—Capecitabine—esophageal cancer	0.000419	0.00547	CcSEcCtD
Oxaprozin—Stomatitis—Cisplatin—esophageal cancer	0.000418	0.00546	CcSEcCtD
Oxaprozin—Conjunctivitis—Cisplatin—esophageal cancer	0.000417	0.00544	CcSEcCtD
Oxaprozin—Cystitis noninfective—Methotrexate—esophageal cancer	0.000411	0.00537	CcSEcCtD
Oxaprozin—Melaena—Methotrexate—esophageal cancer	0.000411	0.00537	CcSEcCtD
Oxaprozin—Gastrointestinal haemorrhage—Capecitabine—esophageal cancer	0.00041	0.00536	CcSEcCtD
Oxaprozin—Cystitis—Methotrexate—esophageal cancer	0.000406	0.00531	CcSEcCtD
Oxaprozin—Aplastic anaemia—Methotrexate—esophageal cancer	0.000395	0.00516	CcSEcCtD
Oxaprozin—Coma—Methotrexate—esophageal cancer	0.000385	0.00502	CcSEcCtD
Oxaprozin—Ecchymosis—Methotrexate—esophageal cancer	0.000381	0.00497	CcSEcCtD
Oxaprozin—Urine output increased—Methotrexate—esophageal cancer	0.000381	0.00497	CcSEcCtD
Oxaprozin—Bladder pain—Methotrexate—esophageal cancer	0.000381	0.00497	CcSEcCtD
Oxaprozin—Abdominal pain upper—Capecitabine—esophageal cancer	0.000375	0.00489	CcSEcCtD
Oxaprozin—Toxic epidermal necrolysis—Capecitabine—esophageal cancer	0.00037	0.00482	CcSEcCtD
Oxaprozin—Sepsis—Methotrexate—esophageal cancer	0.000365	0.00477	CcSEcCtD
Oxaprozin—Gastritis—Capecitabine—esophageal cancer	0.000363	0.00474	CcSEcCtD
Oxaprozin—Tinnitus—Cisplatin—esophageal cancer	0.000359	0.00469	CcSEcCtD
Oxaprozin—Lymphadenopathy—Methotrexate—esophageal cancer	0.000358	0.00467	CcSEcCtD
Oxaprozin—Asthma—Capecitabine—esophageal cancer	0.000355	0.00463	CcSEcCtD
Oxaprozin—Polyuria—Methotrexate—esophageal cancer	0.000348	0.00454	CcSEcCtD
Oxaprozin—Photosensitivity—Methotrexate—esophageal cancer	0.000348	0.00454	CcSEcCtD
Oxaprozin—Sweating increased—Capecitabine—esophageal cancer	0.000346	0.00451	CcSEcCtD
Oxaprozin—Arrhythmia—Cisplatin—esophageal cancer	0.000344	0.00449	CcSEcCtD
Oxaprozin—Alopecia—Cisplatin—esophageal cancer	0.00034	0.00444	CcSEcCtD
Oxaprozin—Hepatic failure—Methotrexate—esophageal cancer	0.00034	0.00444	CcSEcCtD
Oxaprozin—Pancytopenia—Capecitabine—esophageal cancer	0.000337	0.0044	CcSEcCtD
Oxaprozin—Phenylbutazone—PTGS1—esophageal cancer	0.000334	0.0868	CrCbGaD
Oxaprozin—Fenbufen—PTGS2—esophageal cancer	0.000332	0.0863	CrCbGaD
Oxaprozin—Dysuria—Capecitabine—esophageal cancer	0.000332	0.00433	CcSEcCtD
Oxaprozin—Renal failure acute—Methotrexate—esophageal cancer	0.000331	0.00432	CcSEcCtD
Oxaprozin—Flatulence—Cisplatin—esophageal cancer	0.00033	0.00431	CcSEcCtD
Oxaprozin—Dermatitis exfoliative—Methotrexate—esophageal cancer	0.000324	0.00423	CcSEcCtD
Oxaprozin—Photosensitivity reaction—Capecitabine—esophageal cancer	0.000324	0.00423	CcSEcCtD
Oxaprozin—Hyperglycaemia—Capecitabine—esophageal cancer	0.00032	0.00418	CcSEcCtD
Oxaprozin—Pneumonia—Capecitabine—esophageal cancer	0.000318	0.00415	CcSEcCtD
Oxaprozin—Vision blurred—Cisplatin—esophageal cancer	0.000316	0.00413	CcSEcCtD
Oxaprozin—Anaphylactoid reaction—Methotrexate—esophageal cancer	0.000316	0.00412	CcSEcCtD
Oxaprozin—Carbamazepine—ABCC2—esophageal cancer	0.000315	0.0819	CrCbGaD
Oxaprozin—Tremor—Cisplatin—esophageal cancer	0.000314	0.0041	CcSEcCtD
Oxaprozin—Stevens-Johnson syndrome—Capecitabine—esophageal cancer	0.000314	0.00409	CcSEcCtD
Oxaprozin—Acute coronary syndrome—Capecitabine—esophageal cancer	0.000312	0.00407	CcSEcCtD
Oxaprozin—Lethargy—Methotrexate—esophageal cancer	0.000312	0.00407	CcSEcCtD
Oxaprozin—Ill-defined disorder—Cisplatin—esophageal cancer	0.000311	0.00406	CcSEcCtD
Oxaprozin—Renal failure—Capecitabine—esophageal cancer	0.000311	0.00406	CcSEcCtD
Oxaprozin—Myocardial infarction—Capecitabine—esophageal cancer	0.00031	0.00405	CcSEcCtD
Oxaprozin—Anaemia—Cisplatin—esophageal cancer	0.00031	0.00405	CcSEcCtD
Oxaprozin—Stomatitis—Capecitabine—esophageal cancer	0.000308	0.00402	CcSEcCtD
Oxaprozin—Jaundice—Capecitabine—esophageal cancer	0.000308	0.00402	CcSEcCtD
Oxaprozin—Conjunctivitis—Capecitabine—esophageal cancer	0.000307	0.00401	CcSEcCtD
Oxaprozin—Phenytoin—ABCC2—esophageal cancer	0.000306	0.0796	CrCbGaD
Oxaprozin—Malaise—Cisplatin—esophageal cancer	0.000302	0.00395	CcSEcCtD
Oxaprozin—Haematuria—Capecitabine—esophageal cancer	0.000302	0.00394	CcSEcCtD
Oxaprozin—Leukopenia—Cisplatin—esophageal cancer	0.0003	0.00392	CcSEcCtD
Oxaprozin—Agranulocytosis—Capecitabine—esophageal cancer	0.000295	0.00385	CcSEcCtD
Oxaprozin—Convulsion—Cisplatin—esophageal cancer	0.00029	0.00379	CcSEcCtD
Oxaprozin—CYP2C9—Oxidation by Cytochrome P450—CYP26A1—esophageal cancer	0.000288	0.00575	CbGpPWpGaD
Oxaprozin—Haemoglobin—Capecitabine—esophageal cancer	0.000285	0.00373	CcSEcCtD
Oxaprozin—Anxiety—Cisplatin—esophageal cancer	0.000284	0.00371	CcSEcCtD
Oxaprozin—Haemorrhage—Capecitabine—esophageal cancer	0.000284	0.00371	CcSEcCtD
Oxaprozin—Hepatitis—Capecitabine—esophageal cancer	0.000284	0.00371	CcSEcCtD
Oxaprozin—Discomfort—Cisplatin—esophageal cancer	0.000282	0.00368	CcSEcCtD
Oxaprozin—Toxic epidermal necrolysis—Methotrexate—esophageal cancer	0.000275	0.00359	CcSEcCtD
Oxaprozin—Anaphylactic shock—Cisplatin—esophageal cancer	0.000274	0.00357	CcSEcCtD
Oxaprozin—Oedema—Cisplatin—esophageal cancer	0.000274	0.00357	CcSEcCtD
Oxaprozin—Flurbiprofen—PTGS1—esophageal cancer	0.000272	0.0708	CrCbGaD
Oxaprozin—Infection—Cisplatin—esophageal cancer	0.000272	0.00355	CcSEcCtD
Oxaprozin—Erythema multiforme—Capecitabine—esophageal cancer	0.000268	0.0035	CcSEcCtD
Oxaprozin—Thrombocytopenia—Cisplatin—esophageal cancer	0.000268	0.0035	CcSEcCtD
Oxaprozin—Tachycardia—Cisplatin—esophageal cancer	0.000267	0.00349	CcSEcCtD
Oxaprozin—Tinnitus—Capecitabine—esophageal cancer	0.000265	0.00346	CcSEcCtD
Oxaprozin—Hyperhidrosis—Cisplatin—esophageal cancer	0.000265	0.00345	CcSEcCtD
Oxaprozin—Asthma—Methotrexate—esophageal cancer	0.000264	0.00345	CcSEcCtD
Oxaprozin—Eosinophilia—Methotrexate—esophageal cancer	0.000261	0.00341	CcSEcCtD
Oxaprozin—Anorexia—Cisplatin—esophageal cancer	0.000261	0.00341	CcSEcCtD
Oxaprozin—Pancreatitis—Methotrexate—esophageal cancer	0.000259	0.00338	CcSEcCtD
Oxaprozin—PTGS1—Phase 1 - Functionalization of compounds—CYP1B1—esophageal cancer	0.000258	0.00516	CbGpPWpGaD
Oxaprozin—PTGS1—Biological oxidations—ADH1B—esophageal cancer	0.000257	0.00513	CbGpPWpGaD
Oxaprozin—Hypotension—Cisplatin—esophageal cancer	0.000256	0.00334	CcSEcCtD
Oxaprozin—CYP2C9—Phase 1 - Functionalization of compounds—ADH1B—esophageal cancer	0.000254	0.00508	CbGpPWpGaD
Oxaprozin—Arrhythmia—Capecitabine—esophageal cancer	0.000254	0.00331	CcSEcCtD
Oxaprozin—Alopecia—Capecitabine—esophageal cancer	0.000251	0.00328	CcSEcCtD
Oxaprozin—Pancytopenia—Methotrexate—esophageal cancer	0.000251	0.00327	CcSEcCtD
Oxaprozin—PTGS1—Prostaglandin Synthesis and Regulation—PTGS2—esophageal cancer	0.00025	0.00499	CbGpPWpGaD
Oxaprozin—Dysuria—Methotrexate—esophageal cancer	0.000247	0.00322	CcSEcCtD
Oxaprozin—Paraesthesia—Cisplatin—esophageal cancer	0.000246	0.00321	CcSEcCtD
Oxaprozin—Dyspnoea—Cisplatin—esophageal cancer	0.000244	0.00318	CcSEcCtD
Oxaprozin—Flatulence—Capecitabine—esophageal cancer	0.000244	0.00318	CcSEcCtD
Oxaprozin—PTGS1—Phase 1 - Functionalization of compounds—CYP19A1—esophageal cancer	0.000243	0.00485	CbGpPWpGaD
Oxaprozin—Dysgeusia—Capecitabine—esophageal cancer	0.000242	0.00316	CcSEcCtD
Oxaprozin—Photosensitivity reaction—Methotrexate—esophageal cancer	0.000241	0.00315	CcSEcCtD
Oxaprozin—PTGS1—Biological oxidations—CYP26A1—esophageal cancer	0.000239	0.00477	CbGpPWpGaD
Oxaprozin—PTGS2—Signaling mediated by p38-alpha and p38-beta—NOS2—esophageal cancer	0.000239	0.00477	CbGpPWpGaD
Oxaprozin—Decreased appetite—Cisplatin—esophageal cancer	0.000238	0.00311	CcSEcCtD
Oxaprozin—Pneumonia—Methotrexate—esophageal cancer	0.000237	0.00309	CcSEcCtD
Oxaprozin—CYP2C9—Phase 1 - Functionalization of compounds—CYP26A1—esophageal cancer	0.000237	0.00472	CbGpPWpGaD
Oxaprozin—Drowsiness—Methotrexate—esophageal cancer	0.000235	0.00307	CcSEcCtD
Oxaprozin—Stevens-Johnson syndrome—Methotrexate—esophageal cancer	0.000233	0.00305	CcSEcCtD
Oxaprozin—Vision blurred—Capecitabine—esophageal cancer	0.000233	0.00304	CcSEcCtD
Oxaprozin—Tremor—Capecitabine—esophageal cancer	0.000232	0.00302	CcSEcCtD
Oxaprozin—Renal failure—Methotrexate—esophageal cancer	0.000231	0.00302	CcSEcCtD
Oxaprozin—Stomatitis—Methotrexate—esophageal cancer	0.000229	0.003	CcSEcCtD
Oxaprozin—Ill-defined disorder—Capecitabine—esophageal cancer	0.000229	0.00299	CcSEcCtD
Oxaprozin—Conjunctivitis—Methotrexate—esophageal cancer	0.000229	0.00299	CcSEcCtD
Oxaprozin—Anaemia—Capecitabine—esophageal cancer	0.000228	0.00298	CcSEcCtD
Oxaprozin—CYP2C9—Constitutive Androstane Receptor Pathway—ABCB1—esophageal cancer	0.000228	0.00456	CbGpPWpGaD
Oxaprozin—CYP2C9—Arachidonic acid metabolism—PTGS1—esophageal cancer	0.000228	0.00455	CbGpPWpGaD
Oxaprozin—Feeling abnormal—Cisplatin—esophageal cancer	0.000225	0.00294	CcSEcCtD
Oxaprozin—Haematuria—Methotrexate—esophageal cancer	0.000224	0.00293	CcSEcCtD
Oxaprozin—Malaise—Capecitabine—esophageal cancer	0.000223	0.00291	CcSEcCtD
Oxaprozin—PTGS1—Biological oxidations—GSTO1—esophageal cancer	0.000222	0.00444	CbGpPWpGaD
Oxaprozin—Vertigo—Capecitabine—esophageal cancer	0.000222	0.0029	CcSEcCtD
Oxaprozin—Syncope—Capecitabine—esophageal cancer	0.000222	0.00289	CcSEcCtD
Oxaprozin—Leukopenia—Capecitabine—esophageal cancer	0.000221	0.00289	CcSEcCtD
Oxaprozin—Agranulocytosis—Methotrexate—esophageal cancer	0.00022	0.00287	CcSEcCtD
Oxaprozin—PTGS2—Selenium Micronutrient Network—PTGS1—esophageal cancer	0.000219	0.00437	CbGpPWpGaD
Oxaprozin—PTGS2—Integrated Pancreatic Cancer Pathway—FKBP1A—esophageal cancer	0.000219	0.00437	CbGpPWpGaD
Oxaprozin—Palpitations—Capecitabine—esophageal cancer	0.000218	0.00285	CcSEcCtD
Oxaprozin—Methadone—CYP19A1—esophageal cancer	0.000218	0.0567	CrCbGaD
Oxaprozin—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—esophageal cancer	0.000217	0.00434	CbGpPWpGaD
Oxaprozin—Loss of consciousness—Capecitabine—esophageal cancer	0.000217	0.00284	CcSEcCtD
Oxaprozin—Body temperature increased—Cisplatin—esophageal cancer	0.000216	0.00282	CcSEcCtD
Oxaprozin—Hypertension—Capecitabine—esophageal cancer	0.000213	0.00279	CcSEcCtD
Oxaprozin—Haemoglobin—Methotrexate—esophageal cancer	0.000212	0.00277	CcSEcCtD
Oxaprozin—Haemorrhage—Methotrexate—esophageal cancer	0.000211	0.00276	CcSEcCtD
Oxaprozin—Hepatitis—Methotrexate—esophageal cancer	0.000211	0.00276	CcSEcCtD
Oxaprozin—PTGS2—Spinal Cord Injury—LGALS3—esophageal cancer	0.000211	0.00421	CbGpPWpGaD
Oxaprozin—Anxiety—Capecitabine—esophageal cancer	0.00021	0.00274	CcSEcCtD
Oxaprozin—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP2A6—esophageal cancer	0.000208	0.00415	CbGpPWpGaD
Oxaprozin—Discomfort—Capecitabine—esophageal cancer	0.000208	0.00271	CcSEcCtD
Oxaprozin—Dry mouth—Capecitabine—esophageal cancer	0.000206	0.00269	CcSEcCtD
Oxaprozin—CYP2C9—Oxidation by Cytochrome P450—CYP2A6—esophageal cancer	0.000205	0.0041	CbGpPWpGaD
Oxaprozin—Confusional state—Capecitabine—esophageal cancer	0.000203	0.00266	CcSEcCtD
Oxaprozin—Oedema—Capecitabine—esophageal cancer	0.000202	0.00263	CcSEcCtD
Oxaprozin—Infection—Capecitabine—esophageal cancer	0.0002	0.00262	CcSEcCtD
Oxaprozin—Erythema multiforme—Methotrexate—esophageal cancer	0.0002	0.00261	CcSEcCtD
Oxaprozin—Shock—Capecitabine—esophageal cancer	0.000198	0.00259	CcSEcCtD
Oxaprozin—Thrombocytopenia—Capecitabine—esophageal cancer	0.000197	0.00258	CcSEcCtD
Oxaprozin—Tinnitus—Methotrexate—esophageal cancer	0.000197	0.00257	CcSEcCtD
Oxaprozin—Tachycardia—Capecitabine—esophageal cancer	0.000197	0.00257	CcSEcCtD
Oxaprozin—Asthenia—Cisplatin—esophageal cancer	0.000196	0.00256	CcSEcCtD
Oxaprozin—Hyperhidrosis—Capecitabine—esophageal cancer	0.000195	0.00255	CcSEcCtD
Oxaprozin—CYP2C9—Arachidonic acid metabolism—CYP1B1—esophageal cancer	0.000194	0.00387	CbGpPWpGaD
Oxaprozin—Anorexia—Capecitabine—esophageal cancer	0.000192	0.00251	CcSEcCtD
Oxaprozin—Phenylbutazone—PTGS2—esophageal cancer	0.000191	0.0496	CrCbGaD
Oxaprozin—Hypotension—Capecitabine—esophageal cancer	0.000188	0.00246	CcSEcCtD
Oxaprozin—PTGS1—Selenium Micronutrient Network—SOD2—esophageal cancer	0.000188	0.00376	CbGpPWpGaD
Oxaprozin—Diarrhoea—Cisplatin—esophageal cancer	0.000187	0.00244	CcSEcCtD
Oxaprozin—Alopecia—Methotrexate—esophageal cancer	0.000187	0.00244	CcSEcCtD
Oxaprozin—PTGS2—Spinal Cord Injury—CXCL2—esophageal cancer	0.000183	0.00365	CbGpPWpGaD
Oxaprozin—Insomnia—Capecitabine—esophageal cancer	0.000182	0.00238	CcSEcCtD
Oxaprozin—Diphenhydramine—PTGS1—esophageal cancer	0.000182	0.0472	CrCbGaD
Oxaprozin—PTGS1—Biological oxidations—ALDH2—esophageal cancer	0.000181	0.00362	CbGpPWpGaD
Oxaprozin—Paraesthesia—Capecitabine—esophageal cancer	0.000181	0.00236	CcSEcCtD
Oxaprozin—Dysgeusia—Methotrexate—esophageal cancer	0.00018	0.00235	CcSEcCtD
Oxaprozin—Dyspnoea—Capecitabine—esophageal cancer	0.00018	0.00235	CcSEcCtD
Oxaprozin—CYP2C9—Phase 1 - Functionalization of compounds—ALDH2—esophageal cancer	0.000179	0.00358	CbGpPWpGaD
Oxaprozin—Dyspepsia—Capecitabine—esophageal cancer	0.000178	0.00232	CcSEcCtD
Oxaprozin—Decreased appetite—Capecitabine—esophageal cancer	0.000175	0.00229	CcSEcCtD
Oxaprozin—Vomiting—Cisplatin—esophageal cancer	0.000174	0.00227	CcSEcCtD
Oxaprozin—Vision blurred—Methotrexate—esophageal cancer	0.000173	0.00226	CcSEcCtD
Oxaprozin—Rash—Cisplatin—esophageal cancer	0.000173	0.00225	CcSEcCtD
Oxaprozin—Constipation—Capecitabine—esophageal cancer	0.000172	0.00225	CcSEcCtD
Oxaprozin—Dermatitis—Cisplatin—esophageal cancer	0.000172	0.00225	CcSEcCtD
Oxaprozin—PTGS1—Biological oxidations—GSTT1—esophageal cancer	0.000172	0.00344	CbGpPWpGaD
Oxaprozin—PTGS2—Aryl Hydrocarbon Receptor—RB1—esophageal cancer	0.000172	0.00343	CbGpPWpGaD
Oxaprozin—Ill-defined disorder—Methotrexate—esophageal cancer	0.000171	0.00223	CcSEcCtD
Oxaprozin—PTGS1—Biological oxidations—CYP2A6—esophageal cancer	0.00017	0.0034	CbGpPWpGaD
Oxaprozin—PTGS2—Integrated Pancreatic Cancer Pathway—BBC3—esophageal cancer	0.00017	0.00339	CbGpPWpGaD
Oxaprozin—Anaemia—Methotrexate—esophageal cancer	0.00017	0.00222	CcSEcCtD
Oxaprozin—PTGS2—Spinal Cord Injury—ANXA1—esophageal cancer	0.00017	0.00339	CbGpPWpGaD
Oxaprozin—CYP2C9—Phase 1 - Functionalization of compounds—CYP2A6—esophageal cancer	0.000169	0.00337	CbGpPWpGaD
Oxaprozin—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP1B1—esophageal cancer	0.000168	0.00335	CbGpPWpGaD
Oxaprozin—PTGS1—Arachidonic acid metabolism—PTGS2—esophageal cancer	0.000166	0.00332	CbGpPWpGaD
Oxaprozin—Feeling abnormal—Capecitabine—esophageal cancer	0.000166	0.00217	CcSEcCtD
Oxaprozin—Malaise—Methotrexate—esophageal cancer	0.000166	0.00217	CcSEcCtD
Oxaprozin—CYP2C9—Oxidation by Cytochrome P450—CYP1B1—esophageal cancer	0.000165	0.0033	CbGpPWpGaD
Oxaprozin—Vertigo—Methotrexate—esophageal cancer	0.000165	0.00216	CcSEcCtD
Oxaprozin—Gastrointestinal pain—Capecitabine—esophageal cancer	0.000165	0.00215	CcSEcCtD
Oxaprozin—Leukopenia—Methotrexate—esophageal cancer	0.000165	0.00215	CcSEcCtD
Oxaprozin—Nausea—Cisplatin—esophageal cancer	0.000163	0.00212	CcSEcCtD
Oxaprozin—Urticaria—Capecitabine—esophageal cancer	0.00016	0.00209	CcSEcCtD
Oxaprozin—CYP2C9—Phase 1 - Functionalization of compounds—PTGS1—esophageal cancer	0.00016	0.00319	CbGpPWpGaD
Oxaprozin—Body temperature increased—Capecitabine—esophageal cancer	0.000159	0.00208	CcSEcCtD
Oxaprozin—Abdominal pain—Capecitabine—esophageal cancer	0.000159	0.00208	CcSEcCtD
Oxaprozin—Convulsion—Methotrexate—esophageal cancer	0.000159	0.00208	CcSEcCtD
Oxaprozin—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP19A1—esophageal cancer	0.000158	0.00315	CbGpPWpGaD
Oxaprozin—Flurbiprofen—PTGS2—esophageal cancer	0.000156	0.0405	CrCbGaD
Oxaprozin—CYP2C9—Oxidation by Cytochrome P450—CYP19A1—esophageal cancer	0.000156	0.0031	CbGpPWpGaD
Oxaprozin—Discomfort—Methotrexate—esophageal cancer	0.000155	0.00202	CcSEcCtD
Oxaprozin—CYP2C9—Biological oxidations—ADH7—esophageal cancer	0.000154	0.00308	CbGpPWpGaD
Oxaprozin—Propafenone—ABCB1—esophageal cancer	0.000152	0.0394	CrCbGaD
Oxaprozin—Confusional state—Methotrexate—esophageal cancer	0.000151	0.00198	CcSEcCtD
Oxaprozin—Anaphylactic shock—Methotrexate—esophageal cancer	0.00015	0.00196	CcSEcCtD
Oxaprozin—PTGS2—Selenium Micronutrient Network—SOD2—esophageal cancer	0.00015	0.00298	CbGpPWpGaD
Oxaprozin—Infection—Methotrexate—esophageal cancer	0.000149	0.00195	CcSEcCtD
Oxaprozin—Thrombocytopenia—Methotrexate—esophageal cancer	0.000147	0.00192	CcSEcCtD
Oxaprozin—Hyperhidrosis—Methotrexate—esophageal cancer	0.000145	0.0019	CcSEcCtD
Oxaprozin—Asthenia—Capecitabine—esophageal cancer	0.000145	0.00189	CcSEcCtD
Oxaprozin—Anorexia—Methotrexate—esophageal cancer	0.000143	0.00187	CcSEcCtD
Oxaprozin—Pruritus—Capecitabine—esophageal cancer	0.000143	0.00186	CcSEcCtD
Oxaprozin—Hypotension—Methotrexate—esophageal cancer	0.00014	0.00183	CcSEcCtD
Oxaprozin—Diarrhoea—Capecitabine—esophageal cancer	0.000138	0.0018	CcSEcCtD
Oxaprozin—PTGS1—Biological oxidations—CYP1B1—esophageal cancer	0.000137	0.00274	CbGpPWpGaD
Oxaprozin—CYP2C9—Phase 1 - Functionalization of compounds—CYP1B1—esophageal cancer	0.000136	0.00271	CbGpPWpGaD
Oxaprozin—Insomnia—Methotrexate—esophageal cancer	0.000136	0.00177	CcSEcCtD
Oxaprozin—CYP2C9—Biological oxidations—ADH1B—esophageal cancer	0.000135	0.0027	CbGpPWpGaD
Oxaprozin—Paraesthesia—Methotrexate—esophageal cancer	0.000135	0.00176	CcSEcCtD
Oxaprozin—Dyspnoea—Methotrexate—esophageal cancer	0.000134	0.00175	CcSEcCtD
Oxaprozin—Somnolence—Methotrexate—esophageal cancer	0.000133	0.00174	CcSEcCtD
Oxaprozin—Dizziness—Capecitabine—esophageal cancer	0.000133	0.00174	CcSEcCtD
Oxaprozin—PTGS1—Metabolism of lipids and lipoproteins—SLC10A2—esophageal cancer	0.000132	0.00264	CbGpPWpGaD
Oxaprozin—Dyspepsia—Methotrexate—esophageal cancer	0.000132	0.00173	CcSEcCtD
Oxaprozin—Decreased appetite—Methotrexate—esophageal cancer	0.000131	0.0017	CcSEcCtD
Oxaprozin—PTGS1—Biological oxidations—CYP19A1—esophageal cancer	0.000129	0.00258	CbGpPWpGaD
Oxaprozin—Vomiting—Capecitabine—esophageal cancer	0.000128	0.00167	CcSEcCtD
Oxaprozin—CYP2C9—Phase 1 - Functionalization of compounds—CYP19A1—esophageal cancer	0.000128	0.00255	CbGpPWpGaD
Oxaprozin—Rash—Capecitabine—esophageal cancer	0.000127	0.00166	CcSEcCtD
Oxaprozin—Dermatitis—Capecitabine—esophageal cancer	0.000127	0.00166	CcSEcCtD
Oxaprozin—Headache—Capecitabine—esophageal cancer	0.000126	0.00165	CcSEcCtD
Oxaprozin—CYP2C9—Biological oxidations—CYP26A1—esophageal cancer	0.000126	0.00251	CbGpPWpGaD
Oxaprozin—CYP2C9—Metapathway biotransformation—CYP26A1—esophageal cancer	0.000124	0.00247	CbGpPWpGaD
Oxaprozin—Feeling abnormal—Methotrexate—esophageal cancer	0.000124	0.00162	CcSEcCtD
Oxaprozin—PTGS2—Aryl Hydrocarbon Receptor—CDKN1A—esophageal cancer	0.000123	0.00246	CbGpPWpGaD
Oxaprozin—Gastrointestinal pain—Methotrexate—esophageal cancer	0.000123	0.0016	CcSEcCtD
Oxaprozin—Nausea—Capecitabine—esophageal cancer	0.00012	0.00156	CcSEcCtD
Oxaprozin—Urticaria—Methotrexate—esophageal cancer	0.000119	0.00156	CcSEcCtD
Oxaprozin—Body temperature increased—Methotrexate—esophageal cancer	0.000119	0.00155	CcSEcCtD
Oxaprozin—Abdominal pain—Methotrexate—esophageal cancer	0.000119	0.00155	CcSEcCtD
Oxaprozin—PTGS2—Aryl Hydrocarbon Receptor—EP300—esophageal cancer	0.000117	0.00234	CbGpPWpGaD
Oxaprozin—CYP2C9—Biological oxidations—GSTO1—esophageal cancer	0.000117	0.00233	CbGpPWpGaD
Oxaprozin—Carbamazepine—ABCB1—esophageal cancer	0.000116	0.0301	CrCbGaD
Oxaprozin—PTGS2—Integrated Pancreatic Cancer Pathway—ANXA1—esophageal cancer	0.000116	0.00231	CbGpPWpGaD
Oxaprozin—CYP2C9—Metapathway biotransformation—GSTO1—esophageal cancer	0.000115	0.0023	CbGpPWpGaD
Oxaprozin—Phenytoin—ABCB1—esophageal cancer	0.000113	0.0293	CrCbGaD
Oxaprozin—Asthenia—Methotrexate—esophageal cancer	0.000108	0.00141	CcSEcCtD
Oxaprozin—PTGS2—C-MYB transcription factor network—CREBBP—esophageal cancer	0.000106	0.00212	CbGpPWpGaD
Oxaprozin—Pruritus—Methotrexate—esophageal cancer	0.000106	0.00139	CcSEcCtD
Oxaprozin—PTGS1—Selenium Micronutrient Network—PTGS2—esophageal cancer	0.000106	0.00211	CbGpPWpGaD
Oxaprozin—PTGS2—Integrated Pancreatic Cancer Pathway—BUB1B—esophageal cancer	0.000106	0.00211	CbGpPWpGaD
Oxaprozin—PTGS2—Metabolism of lipids and lipoproteins—SLC10A2—esophageal cancer	0.000105	0.0021	CbGpPWpGaD
Oxaprozin—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—esophageal cancer	0.000105	0.00209	CbGpPWpGaD
Oxaprozin—Diarrhoea—Methotrexate—esophageal cancer	0.000103	0.00134	CcSEcCtD
Oxaprozin—PTGS2—Aryl Hydrocarbon Receptor—MYC—esophageal cancer	0.000102	0.00204	CbGpPWpGaD
Oxaprozin—PTGS2—Integrated Pancreatic Cancer Pathway—CHEK2—esophageal cancer	0.000101	0.00201	CbGpPWpGaD
Oxaprozin—PTGS2—Aryl Hydrocarbon Receptor—EGFR—esophageal cancer	0.0001	0.002	CbGpPWpGaD
Oxaprozin—Dizziness—Methotrexate—esophageal cancer	9.93e-05	0.0013	CcSEcCtD
Oxaprozin—Vomiting—Methotrexate—esophageal cancer	9.55e-05	0.00125	CcSEcCtD
Oxaprozin—CYP2C9—Biological oxidations—ALDH2—esophageal cancer	9.52e-05	0.0019	CbGpPWpGaD
Oxaprozin—PTGS2—Spinal Cord Injury—TLR4—esophageal cancer	9.49e-05	0.0019	CbGpPWpGaD
Oxaprozin—Rash—Methotrexate—esophageal cancer	9.47e-05	0.00124	CcSEcCtD
Oxaprozin—Dermatitis—Methotrexate—esophageal cancer	9.46e-05	0.00123	CcSEcCtD
Oxaprozin—Headache—Methotrexate—esophageal cancer	9.41e-05	0.00123	CcSEcCtD
Oxaprozin—PTGS2—C-MYB transcription factor network—CDKN2A—esophageal cancer	9.32e-05	0.00186	CbGpPWpGaD
Oxaprozin—PTGS2—C-MYB transcription factor network—BCL2—esophageal cancer	9.17e-05	0.00183	CbGpPWpGaD
Oxaprozin—CYP2C9—Biological oxidations—GSTT1—esophageal cancer	9.06e-05	0.00181	CbGpPWpGaD
Oxaprozin—PTGS2—Spinal Cord Injury—NOS2—esophageal cancer	9.03e-05	0.0018	CbGpPWpGaD
Oxaprozin—CYP2C9—Biological oxidations—CYP2A6—esophageal cancer	8.95e-05	0.00179	CbGpPWpGaD
Oxaprozin—PTGS1—Metabolism of lipids and lipoproteins—ALOX15—esophageal cancer	8.95e-05	0.00179	CbGpPWpGaD
Oxaprozin—Nausea—Methotrexate—esophageal cancer	8.92e-05	0.00116	CcSEcCtD
Oxaprozin—CYP2C9—Arachidonic acid metabolism—PTGS2—esophageal cancer	8.74e-05	0.00174	CbGpPWpGaD
Oxaprozin—Methadone—ABCB1—esophageal cancer	8.53e-05	0.0222	CrCbGaD
Oxaprozin—PTGS2—Integrated Pancreatic Cancer Pathway—ABL1—esophageal cancer	8.52e-05	0.0017	CbGpPWpGaD
Oxaprozin—CYP2C9—Biological oxidations—PTGS1—esophageal cancer	8.49e-05	0.00169	CbGpPWpGaD
Oxaprozin—PTGS2—Integrated Pancreatic Cancer Pathway—ABCB1—esophageal cancer	8.25e-05	0.00165	CbGpPWpGaD
Oxaprozin—PTGS2—Integrated Pancreatic Cancer Pathway—SMAD4—esophageal cancer	8.25e-05	0.00165	CbGpPWpGaD
Oxaprozin—PTGS2—Spinal Cord Injury—RB1—esophageal cancer	8.08e-05	0.00161	CbGpPWpGaD
Oxaprozin—PTGS2—C-MYB transcription factor network—CCND1—esophageal cancer	7.87e-05	0.00157	CbGpPWpGaD
Oxaprozin—PTGS2—Integrated Pancreatic Cancer Pathway—BAX—esophageal cancer	7.81e-05	0.00156	CbGpPWpGaD
Oxaprozin—PTGS1—Metabolism of lipids and lipoproteins—CRABP1—esophageal cancer	7.81e-05	0.00156	CbGpPWpGaD
Oxaprozin—PTGS2—C-MYB transcription factor network—CDKN1A—esophageal cancer	7.62e-05	0.00152	CbGpPWpGaD
Oxaprozin—PTGS2—C-MYB transcription factor network—EP300—esophageal cancer	7.25e-05	0.00145	CbGpPWpGaD
Oxaprozin—CYP2C9—Biological oxidations—CYP1B1—esophageal cancer	7.22e-05	0.00144	CbGpPWpGaD
Oxaprozin—CYP2C9—Metapathway biotransformation—CYP1B1—esophageal cancer	7.12e-05	0.00142	CbGpPWpGaD
Oxaprozin—PTGS2—Metabolism of lipids and lipoproteins—ALOX15—esophageal cancer	7.1e-05	0.00142	CbGpPWpGaD
Oxaprozin—CYP2C9—Metabolism of lipids and lipoproteins—SLC10A2—esophageal cancer	6.96e-05	0.00139	CbGpPWpGaD
Oxaprozin—PTGS1—Metabolism—BLVRB—esophageal cancer	6.94e-05	0.00138	CbGpPWpGaD
Oxaprozin—PTGS1—Metabolism—SLC52A3—esophageal cancer	6.94e-05	0.00138	CbGpPWpGaD
Oxaprozin—CYP2C9—Biological oxidations—CYP19A1—esophageal cancer	6.79e-05	0.00135	CbGpPWpGaD
Oxaprozin—CYP2C9—Metapathway biotransformation—CYP19A1—esophageal cancer	6.69e-05	0.00134	CbGpPWpGaD
Oxaprozin—PTGS2—Disease—SLC52A3—esophageal cancer	6.58e-05	0.00131	CbGpPWpGaD
Oxaprozin—PTGS2—C-MYB transcription factor network—MYC—esophageal cancer	6.32e-05	0.00126	CbGpPWpGaD
Oxaprozin—PTGS2—Disease—KMT2D—esophageal cancer	6.27e-05	0.00125	CbGpPWpGaD
Oxaprozin—PTGS2—Metabolism of lipids and lipoproteins—CRABP1—esophageal cancer	6.2e-05	0.00124	CbGpPWpGaD
Oxaprozin—PTGS2—Spinal Cord Injury—CCND1—esophageal cancer	6e-05	0.0012	CbGpPWpGaD
Oxaprozin—PTGS1—Metabolism—CA1—esophageal cancer	5.9e-05	0.00118	CbGpPWpGaD
Oxaprozin—PTGS1—Metabolism—SLC10A2—esophageal cancer	5.9e-05	0.00118	CbGpPWpGaD
Oxaprozin—PTGS2—Integrated Pancreatic Cancer Pathway—CASP8—esophageal cancer	5.54e-05	0.00111	CbGpPWpGaD
Oxaprozin—PTGS2—Integrated Pancreatic Cancer Pathway—CREBBP—esophageal cancer	5.52e-05	0.0011	CbGpPWpGaD
Oxaprozin—PTGS2—Metabolism—BLVRB—esophageal cancer	5.51e-05	0.0011	CbGpPWpGaD
Oxaprozin—PTGS2—Metabolism—SLC52A3—esophageal cancer	5.51e-05	0.0011	CbGpPWpGaD
Oxaprozin—PTGS1—Metabolism—CA2—esophageal cancer	5.39e-05	0.00108	CbGpPWpGaD
Oxaprozin—PTGS1—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	5.27e-05	0.00105	CbGpPWpGaD
Oxaprozin—PTGS1—Metabolism—PLCE1—esophageal cancer	5.02e-05	0.001	CbGpPWpGaD
Oxaprozin—PTGS1—Metabolism—ADH7—esophageal cancer	5.02e-05	0.001	CbGpPWpGaD
Oxaprozin—PTGS1—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	4.96e-05	0.00099	CbGpPWpGaD
Oxaprozin—PTGS2—Metabolism of lipids and lipoproteins—PTGS1—esophageal cancer	4.92e-05	0.000983	CbGpPWpGaD
Oxaprozin—PTGS2—Disease—FKBP1A—esophageal cancer	4.86e-05	0.000971	CbGpPWpGaD
Oxaprozin—PTGS2—Spinal Cord Injury—MYC—esophageal cancer	4.81e-05	0.000961	CbGpPWpGaD
Oxaprozin—PTGS2—Integrated Pancreatic Cancer Pathway—BCL2—esophageal cancer	4.76e-05	0.000949	CbGpPWpGaD
Oxaprozin—PTGS2—Disease—WIF1—esophageal cancer	4.75e-05	0.000949	CbGpPWpGaD
Oxaprozin—PTGS2—Disease—DOCK2—esophageal cancer	4.75e-05	0.000949	CbGpPWpGaD
Oxaprozin—PTGS2—Spinal Cord Injury—EGFR—esophageal cancer	4.71e-05	0.00094	CbGpPWpGaD
Oxaprozin—CYP2C9—Metabolism of lipids and lipoproteins—ALOX15—esophageal cancer	4.7e-05	0.000939	CbGpPWpGaD
Oxaprozin—PTGS2—Metabolism—SLC10A2—esophageal cancer	4.68e-05	0.000935	CbGpPWpGaD
Oxaprozin—PTGS2—Metabolism—CA1—esophageal cancer	4.68e-05	0.000935	CbGpPWpGaD
Oxaprozin—PTGS2—Integrated Pancreatic Cancer Pathway—ERBB2—esophageal cancer	4.62e-05	0.000922	CbGpPWpGaD
Oxaprozin—PTGS1—Metabolism—ADH1B—esophageal cancer	4.4e-05	0.000878	CbGpPWpGaD
Oxaprozin—PTGS2—Disease—CSNK1A1—esophageal cancer	4.39e-05	0.000876	CbGpPWpGaD
Oxaprozin—PTGS2—Metabolism—CA2—esophageal cancer	4.28e-05	0.000855	CbGpPWpGaD
Oxaprozin—PTGS1—Metabolism—TYMP—esophageal cancer	4.2e-05	0.000839	CbGpPWpGaD
Oxaprozin—PTGS2—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	4.19e-05	0.000835	CbGpPWpGaD
Oxaprozin—CYP2C9—Metabolism of lipids and lipoproteins—CRABP1—esophageal cancer	4.1e-05	0.000819	CbGpPWpGaD
Oxaprozin—PTGS1—Metabolism—CYP26A1—esophageal cancer	4.09e-05	0.000816	CbGpPWpGaD
Oxaprozin—PTGS2—Integrated Pancreatic Cancer Pathway—CCND1—esophageal cancer	4.08e-05	0.000815	CbGpPWpGaD
Oxaprozin—PTGS1—Metabolism—ALOX15—esophageal cancer	3.98e-05	0.000795	CbGpPWpGaD
Oxaprozin—PTGS2—Metabolism—ADH7—esophageal cancer	3.98e-05	0.000795	CbGpPWpGaD
Oxaprozin—PTGS2—Metabolism—PLCE1—esophageal cancer	3.98e-05	0.000795	CbGpPWpGaD
Oxaprozin—PTGS2—Spinal Cord Injury—TP53—esophageal cancer	3.95e-05	0.000789	CbGpPWpGaD
Oxaprozin—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN1A—esophageal cancer	3.95e-05	0.000788	CbGpPWpGaD
Oxaprozin—PTGS2—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	3.94e-05	0.000786	CbGpPWpGaD
Oxaprozin—PTGS1—Metabolism—TPI1—esophageal cancer	3.8e-05	0.000759	CbGpPWpGaD
Oxaprozin—PTGS1—Metabolism—GSTO1—esophageal cancer	3.8e-05	0.000759	CbGpPWpGaD
Oxaprozin—PTGS2—Integrated Pancreatic Cancer Pathway—EP300—esophageal cancer	3.76e-05	0.00075	CbGpPWpGaD
Oxaprozin—PTGS2—Disease—ELMO1—esophageal cancer	3.69e-05	0.000736	CbGpPWpGaD
Oxaprozin—CYP2C9—Metabolism—SLC52A3—esophageal cancer	3.65e-05	0.000728	CbGpPWpGaD
Oxaprozin—CYP2C9—Metabolism—BLVRB—esophageal cancer	3.65e-05	0.000728	CbGpPWpGaD
Oxaprozin—PTGS1—Metabolism—ALDOB—esophageal cancer	3.64e-05	0.000727	CbGpPWpGaD
Oxaprozin—PTGS2—Disease—GSTO1—esophageal cancer	3.6e-05	0.000719	CbGpPWpGaD
Oxaprozin—PTGS2—Disease—TPI1—esophageal cancer	3.6e-05	0.000719	CbGpPWpGaD
Oxaprozin—PTGS1—Metabolism—GAPDH—esophageal cancer	3.51e-05	0.0007	CbGpPWpGaD
Oxaprozin—PTGS2—Metabolism—ADH1B—esophageal cancer	3.49e-05	0.000697	CbGpPWpGaD
Oxaprozin—PTGS1—Metabolism—CRABP1—esophageal cancer	3.48e-05	0.000694	CbGpPWpGaD
Oxaprozin—PTGS2—Disease—ALDOB—esophageal cancer	3.45e-05	0.000689	CbGpPWpGaD
Oxaprozin—PTGS2—Metabolism—TYMP—esophageal cancer	3.34e-05	0.000666	CbGpPWpGaD
Oxaprozin—PTGS2—Disease—HIST1H2BM—esophageal cancer	3.32e-05	0.000664	CbGpPWpGaD
Oxaprozin—PTGS2—Disease—GAPDH—esophageal cancer	3.32e-05	0.000664	CbGpPWpGaD
Oxaprozin—PTGS1—Metabolism—GNG7—esophageal cancer	3.31e-05	0.00066	CbGpPWpGaD
Oxaprozin—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—esophageal cancer	3.27e-05	0.000654	CbGpPWpGaD
Oxaprozin—CYP2C9—Metabolism of lipids and lipoproteins—PTGS1—esophageal cancer	3.26e-05	0.000651	CbGpPWpGaD
Oxaprozin—PTGS2—Metabolism—CYP26A1—esophageal cancer	3.25e-05	0.000648	CbGpPWpGaD
Oxaprozin—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—esophageal cancer	3.2e-05	0.000639	CbGpPWpGaD
Oxaprozin—PTGS2—Metabolism—ALOX15—esophageal cancer	3.16e-05	0.000631	CbGpPWpGaD
Oxaprozin—CYP2C9—Metabolism—CA1—esophageal cancer	3.1e-05	0.000619	CbGpPWpGaD
Oxaprozin—CYP2C9—Metabolism—SLC10A2—esophageal cancer	3.1e-05	0.000619	CbGpPWpGaD
Oxaprozin—PTGS1—Metabolism—ALDH2—esophageal cancer	3.1e-05	0.000618	CbGpPWpGaD
Oxaprozin—PTGS2—Metabolism—GSTO1—esophageal cancer	3.02e-05	0.000602	CbGpPWpGaD
Oxaprozin—PTGS2—Metabolism—TPI1—esophageal cancer	3.02e-05	0.000602	CbGpPWpGaD
Oxaprozin—PTGS1—Metabolism—GSTT1—esophageal cancer	2.95e-05	0.000588	CbGpPWpGaD
Oxaprozin—PTGS2—Disease—XIAP—esophageal cancer	2.94e-05	0.000586	CbGpPWpGaD
Oxaprozin—PTGS1—Metabolism—CYP2A6—esophageal cancer	2.91e-05	0.000581	CbGpPWpGaD
Oxaprozin—PTGS1—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	2.9e-05	0.000579	CbGpPWpGaD
Oxaprozin—PTGS2—Metabolism—ALDOB—esophageal cancer	2.89e-05	0.000577	CbGpPWpGaD
Oxaprozin—CYP2C9—Metabolism—CA2—esophageal cancer	2.84e-05	0.000566	CbGpPWpGaD
Oxaprozin—PTGS2—Metabolism—GAPDH—esophageal cancer	2.78e-05	0.000556	CbGpPWpGaD
Oxaprozin—PTGS2—Integrated Pancreatic Cancer Pathway—PIK3CA—esophageal cancer	2.78e-05	0.000555	CbGpPWpGaD
Oxaprozin—CYP2C9—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	2.77e-05	0.000553	CbGpPWpGaD
Oxaprozin—PTGS1—Metabolism—ENO1—esophageal cancer	2.76e-05	0.000551	CbGpPWpGaD
Oxaprozin—PTGS2—Metabolism—CRABP1—esophageal cancer	2.76e-05	0.000551	CbGpPWpGaD
Oxaprozin—PTGS2—Disease—B2M—esophageal cancer	2.73e-05	0.000545	CbGpPWpGaD
Oxaprozin—PTGS1—Metabolism—PSME2—esophageal cancer	2.72e-05	0.000543	CbGpPWpGaD
Oxaprozin—PTGS1—Metabolism—PSME1—esophageal cancer	2.72e-05	0.000543	CbGpPWpGaD
Oxaprozin—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—esophageal cancer	2.69e-05	0.000537	CbGpPWpGaD
Oxaprozin—CYP2C9—Metabolism—ADH7—esophageal cancer	2.64e-05	0.000526	CbGpPWpGaD
Oxaprozin—CYP2C9—Metabolism—PLCE1—esophageal cancer	2.64e-05	0.000526	CbGpPWpGaD
Oxaprozin—PTGS2—Metabolism—GNG7—esophageal cancer	2.62e-05	0.000524	CbGpPWpGaD
Oxaprozin—PTGS2—Disease—ENO1—esophageal cancer	2.62e-05	0.000523	CbGpPWpGaD
Oxaprozin—CYP2C9—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	2.61e-05	0.00052	CbGpPWpGaD
Oxaprozin—PTGS2—Disease—PSME2—esophageal cancer	2.58e-05	0.000515	CbGpPWpGaD
Oxaprozin—PTGS2—Disease—PSME1—esophageal cancer	2.58e-05	0.000515	CbGpPWpGaD
Oxaprozin—PTGS2—Disease—CALR—esophageal cancer	2.48e-05	0.000494	CbGpPWpGaD
Oxaprozin—PTGS2—Metabolism—ALDH2—esophageal cancer	2.46e-05	0.000491	CbGpPWpGaD
Oxaprozin—PTGS2—Disease—FBXW7—esophageal cancer	2.39e-05	0.000478	CbGpPWpGaD
Oxaprozin—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	2.38e-05	0.000474	CbGpPWpGaD
Oxaprozin—PTGS1—Metabolism—CYP1B1—esophageal cancer	2.35e-05	0.000469	CbGpPWpGaD
Oxaprozin—PTGS2—Metabolism—GSTT1—esophageal cancer	2.34e-05	0.000467	CbGpPWpGaD
Oxaprozin—PTGS2—Metabolism—CYP2A6—esophageal cancer	2.31e-05	0.000462	CbGpPWpGaD
Oxaprozin—CYP2C9—Metabolism—ADH1B—esophageal cancer	2.31e-05	0.000461	CbGpPWpGaD
Oxaprozin—PTGS2—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	2.3e-05	0.00046	CbGpPWpGaD
Oxaprozin—CYP2C9—Metabolism—TYMP—esophageal cancer	2.21e-05	0.000441	CbGpPWpGaD
Oxaprozin—PTGS1—Metabolism—CYP19A1—esophageal cancer	2.21e-05	0.000441	CbGpPWpGaD
Oxaprozin—PTGS2—Metabolism—ENO1—esophageal cancer	2.19e-05	0.000438	CbGpPWpGaD
Oxaprozin—PTGS2—Metabolism—PTGS1—esophageal cancer	2.19e-05	0.000438	CbGpPWpGaD
Oxaprozin—PTGS2—Metabolism—PSME2—esophageal cancer	2.16e-05	0.000431	CbGpPWpGaD
Oxaprozin—PTGS2—Metabolism—PSME1—esophageal cancer	2.16e-05	0.000431	CbGpPWpGaD
Oxaprozin—CYP2C9—Metabolism—CYP26A1—esophageal cancer	2.15e-05	0.000429	CbGpPWpGaD
Oxaprozin—CYP2C9—Metabolism—ALOX15—esophageal cancer	2.09e-05	0.000418	CbGpPWpGaD
Oxaprozin—PTGS1—Metabolism—HMOX1—esophageal cancer	2.01e-05	0.000402	CbGpPWpGaD
Oxaprozin—CYP2C9—Metabolism—GSTO1—esophageal cancer	2e-05	0.000399	CbGpPWpGaD
Oxaprozin—CYP2C9—Metabolism—TPI1—esophageal cancer	2e-05	0.000399	CbGpPWpGaD
Oxaprozin—PTGS1—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	1.98e-05	0.000395	CbGpPWpGaD
Oxaprozin—PTGS2—Disease—TGFBR2—esophageal cancer	1.94e-05	0.000387	CbGpPWpGaD
Oxaprozin—PTGS1—Metabolism—ABCB1—esophageal cancer	1.93e-05	0.000386	CbGpPWpGaD
Oxaprozin—CYP2C9—Metabolism—ALDOB—esophageal cancer	1.92e-05	0.000382	CbGpPWpGaD
Oxaprozin—PTGS2—Metabolism—CYP1B1—esophageal cancer	1.86e-05	0.000372	CbGpPWpGaD
Oxaprozin—CYP2C9—Metabolism—GAPDH—esophageal cancer	1.84e-05	0.000368	CbGpPWpGaD
Oxaprozin—PTGS2—Disease—SMAD4—esophageal cancer	1.83e-05	0.000366	CbGpPWpGaD
Oxaprozin—CYP2C9—Metabolism—CRABP1—esophageal cancer	1.83e-05	0.000365	CbGpPWpGaD
Oxaprozin—PTGS2—Metabolism—CYP19A1—esophageal cancer	1.75e-05	0.00035	CbGpPWpGaD
Oxaprozin—CYP2C9—Metabolism—GNG7—esophageal cancer	1.74e-05	0.000347	CbGpPWpGaD
Oxaprozin—CYP2C9—Metabolism—ALDH2—esophageal cancer	1.63e-05	0.000325	CbGpPWpGaD
Oxaprozin—PTGS2—Metabolism—HMOX1—esophageal cancer	1.6e-05	0.000319	CbGpPWpGaD
Oxaprozin—PTGS2—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	1.57e-05	0.000313	CbGpPWpGaD
Oxaprozin—CYP2C9—Metabolism—GSTT1—esophageal cancer	1.55e-05	0.000309	CbGpPWpGaD
Oxaprozin—PTGS2—Metabolism—ABCB1—esophageal cancer	1.54e-05	0.000306	CbGpPWpGaD
Oxaprozin—CYP2C9—Metabolism—CYP2A6—esophageal cancer	1.53e-05	0.000306	CbGpPWpGaD
Oxaprozin—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	1.53e-05	0.000305	CbGpPWpGaD
Oxaprozin—PTGS2—Disease—HIF1A—esophageal cancer	1.5e-05	0.000299	CbGpPWpGaD
Oxaprozin—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	1.46e-05	0.000292	CbGpPWpGaD
Oxaprozin—CYP2C9—Metabolism—ENO1—esophageal cancer	1.45e-05	0.00029	CbGpPWpGaD
Oxaprozin—CYP2C9—Metabolism—PTGS1—esophageal cancer	1.45e-05	0.00029	CbGpPWpGaD
Oxaprozin—CYP2C9—Metabolism—PSME2—esophageal cancer	1.43e-05	0.000286	CbGpPWpGaD
Oxaprozin—CYP2C9—Metabolism—PSME1—esophageal cancer	1.43e-05	0.000286	CbGpPWpGaD
Oxaprozin—PTGS2—Disease—NOS2—esophageal cancer	1.36e-05	0.000272	CbGpPWpGaD
Oxaprozin—PTGS2—Disease—NOTCH1—esophageal cancer	1.35e-05	0.00027	CbGpPWpGaD
Oxaprozin—PTGS1—Metabolism—CREBBP—esophageal cancer	1.29e-05	0.000258	CbGpPWpGaD
Oxaprozin—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	1.25e-05	0.000249	CbGpPWpGaD
Oxaprozin—CYP2C9—Metabolism—CYP1B1—esophageal cancer	1.23e-05	0.000246	CbGpPWpGaD
Oxaprozin—PTGS2—Disease—CREBBP—esophageal cancer	1.23e-05	0.000245	CbGpPWpGaD
Oxaprozin—CYP2C9—Metabolism—CYP19A1—esophageal cancer	1.16e-05	0.000232	CbGpPWpGaD
Oxaprozin—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	1.16e-05	0.000232	CbGpPWpGaD
Oxaprozin—PTGS1—Metabolism—NOS3—esophageal cancer	1.16e-05	0.000231	CbGpPWpGaD
Oxaprozin—PTGS2—Disease—NOS3—esophageal cancer	1.1e-05	0.000219	CbGpPWpGaD
Oxaprozin—CYP2C9—Metabolism—HMOX1—esophageal cancer	1.06e-05	0.000211	CbGpPWpGaD
Oxaprozin—PTGS1—Metabolism—PTGS2—esophageal cancer	1.06e-05	0.000211	CbGpPWpGaD
Oxaprozin—CYP2C9—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	1.04e-05	0.000207	CbGpPWpGaD
Oxaprozin—PTGS2—Metabolism—CREBBP—esophageal cancer	1.03e-05	0.000205	CbGpPWpGaD
Oxaprozin—PTGS2—Disease—ERBB2—esophageal cancer	1.03e-05	0.000205	CbGpPWpGaD
Oxaprozin—CYP2C9—Metabolism—ABCB1—esophageal cancer	1.02e-05	0.000203	CbGpPWpGaD
Oxaprozin—PTGS2—Metabolism—NOS3—esophageal cancer	9.19e-06	0.000183	CbGpPWpGaD
Oxaprozin—PTGS1—Metabolism—EP300—esophageal cancer	8.8e-06	0.000176	CbGpPWpGaD
Oxaprozin—PTGS2—Disease—CDKN1A—esophageal cancer	8.77e-06	0.000175	CbGpPWpGaD
Oxaprozin—PTGS2—Disease—EP300—esophageal cancer	8.34e-06	0.000167	CbGpPWpGaD
Oxaprozin—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	7.69e-06	0.000153	CbGpPWpGaD
Oxaprozin—PTGS2—Disease—MYC—esophageal cancer	7.27e-06	0.000145	CbGpPWpGaD
Oxaprozin—PTGS2—Disease—EGFR—esophageal cancer	7.11e-06	0.000142	CbGpPWpGaD
Oxaprozin—PTGS2—Metabolism—EP300—esophageal cancer	6.99e-06	0.000139	CbGpPWpGaD
Oxaprozin—CYP2C9—Metabolism—CREBBP—esophageal cancer	6.79e-06	0.000136	CbGpPWpGaD
Oxaprozin—PTGS1—Metabolism—PIK3CA—esophageal cancer	6.51e-06	0.00013	CbGpPWpGaD
Oxaprozin—PTGS2—Disease—PIK3CA—esophageal cancer	6.17e-06	0.000123	CbGpPWpGaD
Oxaprozin—CYP2C9—Metabolism—NOS3—esophageal cancer	6.08e-06	0.000121	CbGpPWpGaD
Oxaprozin—CYP2C9—Metabolism—PTGS2—esophageal cancer	5.56e-06	0.000111	CbGpPWpGaD
Oxaprozin—PTGS2—Metabolism—PIK3CA—esophageal cancer	5.17e-06	0.000103	CbGpPWpGaD
Oxaprozin—CYP2C9—Metabolism—EP300—esophageal cancer	4.63e-06	9.24e-05	CbGpPWpGaD
Oxaprozin—CYP2C9—Metabolism—PIK3CA—esophageal cancer	3.42e-06	6.83e-05	CbGpPWpGaD
